SHUKRA PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.8 INR | -1.99% |
|
-9.38% | +225.98% |
| Sales 2022 | 20Cr 24.57L | Sales 2023 | 59Cr 71.33L | Capitalization | 51Cr 61.66L |
|---|---|---|---|---|---|
| Net income 2022 | 70L 83.92T | Net income 2023 | 4.4Cr 5L | EV / Sales 2022 | 0.62 x |
| Net Debt 2022 | 3.29Cr 4L | Net Debt 2023 | 1.11Cr 1L | EV / Sales 2023 | 0.88 x |
| P/E ratio 2022 |
12.6
x | P/E ratio 2023 |
1.79
x | Employees | 182 |
| Yield 2022 |
0.83% | Yield 2023 |
1.07% | Free-Float | 42.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.99% | ||
| 1 week | -9.38% | ||
| 1 month | +5.92% | ||
| 3 months | +26.28% | ||
| 6 months | +320.65% | ||
| Current year | +225.98% |
1 week
100.85
106.89
1 month
95.17120.64
Current year
30.75120.64
1 year
20.43120.64
3 years
10.44120.64
5 years
6.16120.64
10 years
6.16120.64
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 27 | 11/20/11 | |
| Chairman | 51 | 26/12/26 | |
Arpita Kabra
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 51 | 26/12/26 | |
| Director/Board Member | 43 | 23/12/23 | |
| Director/Board Member | - | 12/23/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 100.8 | -1.99% | 2,681 |
| 30/24/30 | 102.9 | -2.00% | 3,325 |
| 29/24/29 | 105 | -1.77% | 11,117 |
| 28/24/28 | 106.9 | -2.00% | 6,974 |
| 27/24/27 | 109.1 | -1.99% | 5,238 |
Delayed Quote Bombay S.E., May 31, 2024 at 03:30 pm IST
More quotes
Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.
Sector
Pharmaceuticals
Calendar
02/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +225.98% | 5.29Cr | |
| +15.91% | 4.2TCr | |
| +22.56% | 2.23TCr | |
| +18.48% | 1.52TCr | |
| +16.12% | 1.4TCr | |
| +45.12% | 1.21TCr | |
| -9.84% | 679.6Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +14.18% | 549.33Cr |
- Stock Market
- Equities
- SHUKRAPHAR6 Stock
